Sarcopenia Identification Using Alternative Vertebral Landmarks in Individuals with Lung Cancer
Open Access
Abstract
(1) Background: Sarcopenia, or low skeletal mass index (SMI), contributes to higher lung cancer mortality. The SMI at third lumbar vertebrae (L3) is the reference standard for body composition analysis. However, there is a need to explore the validity of alternative landmarks in this population. We compared the agreement of sarcopenia identification at the first lumbar (L1) and second lumbar (L2) to L3 in non-Hispanic Black (NHB) and White (NHW) individuals with lung cancer. (2) Methods: This retrospective, cross-sectional study included 214 NHB and NHW adults with lung cancer. CT scans were analyzed to calculate the SMI at L1, L2, and L3. T-tests, chi-square, Pearson’s correlation, Cohen’s kappa, sensitivity, and specificity analysis were used. (3) Results: Subjects presented with a mean age of 68.4 ± 9.9 years and BMI of 26.3 ± 6.0 kg/m2. Sarcopenia prevalence varied from 19.6% at L1 to 39.7% at L3. Cohen’s kappa coefficient was 0.46 for L1 and 0.64 for L2, indicating weak and moderate agreement for the identification of sarcopenia compared to L3. (4) Conclusions: Sarcopenia prevalence varied greatly depending on the vertebral landmark used for assessment. Using L2 or L1 alone resulted in a 16.8% and 23.8% misclassification of sarcopenia in this cohort of individuals with lung cancer.Keywords
Funding Information
- National Cancer Institute (T32CA057699)
This publication has 29 references indexed in Scilit:
- Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancerBreast Cancer Research and Treatment, 2021
- The use of alternate vertebral levels to L3 in computed tomography scans for skeletal muscle mass evaluation and sarcopenia assessment in patients with cancer: a systematic reviewBritish Journal of Nutrition, 2021
- A Machine Learning Algorithm to Estimate Sarcopenia on Abdominal CTAcademic Radiology, 2020
- Scaling of adult human bone and skeletal muscle mass to height in the US populationAmerican Journal of Human Biology, 2019
- Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)Supportive Care in Cancer, 2018
- Evaluation of sarcopenia in small-cell lung cancer patients by routine chest CTSupportive Care in Cancer, 2016
- Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancerSupportive Care in Cancer, 2015
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Ethnicity‐related skeletal muscle differences across the lifespanAmerican Journal of Human Biology, 2009
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008